Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1G2032R and ALKG1202R

• Main Authors: Siming Liu (Author), Chuan Huang (Author), Chunhui Huang (Author), Yaqi Huang (Author), Yonghuan Yu (Author), Guowu Wu (Author), Fengqiu Guo (Author), Ying Jiang (Author), Shanhe Wan (Author), Zhengguang Zhu (Author), Yuanxin Tian (Author), Jianghua Zhu (Author), Jiajie Zhang (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Clinical treatment by FDA-approved ROS1/ALK inhibitor Crizotinib significantly improved the therapeutic outcomes. However, the emergence of drug resistance, especially driven by acquired mutations, have become an inevitable problem and worsened the clinical effects of Crizotinib. To combat drug resi...